|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Concentrations of tumor nuclear factor-receptor 2 (TNF-R2), e-selectin, and endostatin were significantly lower after consumption of the RP diet compared with WP (p < 0.05).
|
30685298 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent findings highlight the importance of TNFR2 as a key regulator of activated natural FoxP3<sup>+</sup> regulatory T cells (Tregs) in inflammatory conditions, such as acute graft-vs.-host disease (GvHD) and the tumor microenvironment.
|
31555271 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape.
|
30628200 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings show that cell survival genes mediated by TNF/TNFR2 binding is up-regulated in GC favoring its pro-tumoral effect, while pro-apoptotic genes as CASP3 and TNFR1 are down-regulated, indicating disbalance between apoptosis and cell proliferation processes in this neoplasm.
|
31040894 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline burden T<sub>reg</sub>/T effector (T<sub>eff</sub>) ratios and the responsiveness of tumor and infiltrating T<sub>regs</sub> to TNFR2 antibody killing was studied.
|
30356161 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We summarize the recent progress in understanding how TNFR2-dependent mechanisms promote carcinogenesis and tumor growth and discuss the potential value of TNFR2 in cancer treatment.
|
29892300 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the combination of TNFR2-blocking antibody and a CD25-targeted antibody also resulted in enhanced inhibition of tumor growth in a syngeneic 4T1 mouse model of breast cancer.
|
29295954 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High expression and role of tumor necrosis factor receptor 2 (TNFR2) in cancer progression and prognosis has been reported in several types of tumors.
|
30127886 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, the role of TNFR2 has attracted much attention for its promotion role in several types of tumors.
|
29920311 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.
|
29802567 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently, due to the distribution of TNFR2 and its pleiotropic effects, TNFR2 appears to be critical to keeping the balance between Tregs and Teffs, and may be an efficient therapeutic target for tumor and autoimmune diseases.
|
29623079 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Results showed that both peripheral and tumor infiltrating TNFR2<sup>+</sup>Tregs significantly increased in patients with CIN and CC and levels of circulating s-TNFR1 and s-TNFR2 increased in patients with CC.
|
29435163 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinical Relevance of a Candidate Stem Cell Marker, p75 Neurotrophin Receptor (p75NTR) Expression in Circulating Tumor Cells.
|
28560678 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TNFR2 expression (P=0.017), age (P=0.011), menopausal status (P<0.0001), tumor size (P=0.016), clinical stage (P=0.005), pathological grade (P=0.002) and estrogen/progesterone receptor and HER2 triple-status (P=0.008) were all shown to significantly impact the DFS rate of patients with BC.
|
28789455 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These TNFR2 antibodies killed T<sub>regs</sub> isolated from ovarian cancer ascites more potently than it killed T<sub>regs</sub> from healthy donor samples, suggesting that these antibodies may have specificity for the tumor microenvironment.
|
28096513 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also posit that TNFR2 inhibitors might potentially constitute safer and more targeted alternatives to ICI cancer treatment because the expression of TNFR2 on immune cells, concentrated in the tumor microenvironment of various cancers, appears to be more selective than that of checkpoint molecules.
|
29032004 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A neurotrophin receptor p75 (p75NTR) is expressed in a candidate stem cell fraction in esophageal squamous cell carcinoma (ESCC), which shows significantly higher colony formation, enhanced tumor formation in mice, along with strong expression of epithelial mesenchymal transition-related genes.
|
28819854 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro and in vivo fluorescence imaging results suggest peptide P75 modified magnetosomes (Mag-P75) specifically bind to MDA-MB-468 and SKBR3 cells as well as xenograft tumors with surprisingly low accumulation in other organs including liver and kidney.
|
27888699 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, the role of the crosstalk between mTNF-α and TNFR2 in the tumor microenvironment will be discussed.
|
29234328 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In such animals, TNFR2-specific agonists inhibited tumor growth, enhanced tumor infiltration by CD8+ T cells and increased CD8+ T cell IFN-γ synthesis.
|
27626702 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BF-rTK + GCV induced tumor apoptosis mediated by FasL and TNFR2 through the mitochondrial control of apoptosis via Bid and Bim without inducing necroptosis and autophagy.
|
27464624 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The interaction of tumor necrosis factor-α (TNF-α) with its receptors: TNFRSF1A and TNFRSF1B is critical for the promotion of tumor growth, invasion and metastasis.
|
25010932 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNFR1 and TNFR2 were mainly localized in the epithelial neoplastic cells of the tumor.
|
24511008 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increased expression of p75 neurotrophin receptor (NTR) is a characteristic of high-grade glioma, but the potential significance of increased p75NTR in this tumor is not fully understood.
|
23576602 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, metastasis to the lung was observed in a few cases following development of mammary tumors in p75 CUX1 transgenic mice.
|
20224295 |
2011 |